Patents by Inventor Xiaoxin QI

Xiaoxin QI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230203042
    Abstract: The present invention provides compounds of Formula (I) which can be used as Syk inhibitors and potently as therapeutic agents against diseases mediated by Syk.
    Type: Application
    Filed: May 28, 2021
    Publication date: June 29, 2023
    Applicant: NANJING RUIJIE PHARMA CO., LTD.
    Inventors: Junbo ZHANG, Shuhao ZHU, Xiaoxin QI
  • Publication number: 20230002405
    Abstract: The present invention provides a compound suitable for use as an acetyl CoA carboxylase (ACC) inhibitor, specifically, a thienopyridine derivative, and use of the compound in the preparation of drugs for treating metabolic disorders, cancers or other proliferative disorders, and nonalcoholic steatohepatitis (NASH).
    Type: Application
    Filed: November 6, 2020
    Publication date: January 5, 2023
    Applicant: NANJING RUIJIE PHARMA CO., LTD.
    Inventors: Junbo ZHANG, Shuhao ZHU, Xiaoxin QI
  • Publication number: 20220227745
    Abstract: Provided herein are compounds of Formula (I), a stereoisomer, enantiomer or a pharmaceutically acceptable salt thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: June 12, 2020
    Publication date: July 21, 2022
    Inventors: Junbo Zhang, Shuhao Zhu, Xiaoxin Qi
  • Publication number: 20220162161
    Abstract: A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.
    Type: Application
    Filed: February 20, 2020
    Publication date: May 26, 2022
    Applicant: Nanjing Ruijie Pharma Co., Ltd.
    Inventors: Junbo ZHANG, Xiaoxin QI